Since lipid hydrolases are key enzymes in all living organisms, their dysfunction can lead to widespread diseases such as obesity, type 2 diabetes, non-alcoholic fatty liver and cancer, which pose a serious challenge to the health care system. Many of these enzymes are unknown. Researchers of the special research program "SFB LIPID HYDROLYSIS" coordinated by the Med Uni Graz, aim to identify and characterize lipid hydrolases to better understand their involvement in metabolic diseases for future treatments.

Dagmar Kratky

"An in-depth understanding of the structure, function, and physiological relevance of lipid hydrolases should lead to the unraveling of disease mechanisms and thus the discovery of new treatment strategies."

Dagmar Kratky, Speaker SFB

Project Management

Vanessa Csitkovits,  PhD
Neue Stiftingtalstrasse 6/VI, 8010 Graz
T: +43 316 385 71977
F: +43 316 385 79615


Logo Lipidhydrolysis


This SFB unites the expertise of scientists from Graz and Vienna to identify the relationships between lipid and energy metabolism and the pathogenesis of metabolic diseases such as obesity, type 2 diabetes, non-alcoholic fatty liver/steatohepatitis, and cancer. Once the effects of intracellular lipid hydrolases on lipid degradation pathways are known, new treatment strategies for these common diseases can be developed as a long-term goal.


Unsere Strategien


  • Identification and initial biochemical characterization of all predicted lipid hydrolases using an innovative unbiased screening platform;
  • Elucidating the physiological function of lipid hydrolases using established and novel mutant models;
  • Describing the complex reaction pathways and regulatory network of lipolysis by combining biochemical experiments, mathematical models, advanced analytical methods, and structural biology;
  • Exploring the role of lipid hydrolases in disease.

Spezialforschungsbereich Lipidhydrolyse

Video aus der Reihe "Wissenswert"

Gefördert von